Several cardiovascular diseases, such as myocardial fibrosis, heart failure, cardiomyopathy, and pulmonary hypertension, have been found to be associated with changes in the myocardial VIP concentration or with alterations to the affinity, density, and physiological responsiveness of VIP/PACAP receptors [32]. This evidence concerns the gene VIP and pulmonary hypertension.